Brucellosis

Disclaimer: This information is provided for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment or treatment. Clinicians must always use their independent clinical judgment and consider the individual patient's condition, available resources, and the most current evidence-based guidelines.

Overview

• Definition: Brucellosis is a zoonotic infectious disease caused by bacteria of the genus Brucella. It is a systemic infection that can affect multiple organ systems, often characterized by a fluctuating fever, sweating, arthralgia, and fatigue. It is also known as undulant fever, Mediterranean fever, Malta fever, or Bang's disease.

• Epidemiology:

  • Global Distribution: Brucellosis is one of the most widespread zoonoses globally, endemic in many parts of the world, particularly the Mediterranean basin (Spain, Portugal, Italy, Greece), the Middle East, Latin America, Africa, and parts of Asia.
  • Reservoirs: Primarily affects domestic animals (goats, sheep, cattle, pigs, camels, dogs). Brucella melitensis (sheep, goats) is the most common cause of human brucellosis worldwide due to its high pathogenicity and prevalence in milk and dairy products. B. abortus (cattle), B. suis (pigs), and B. canis (dogs) are less common but also significant human pathogens.
  • Transmission:
    • Direct Contact: Exposure to infected animal tissues (blood, placenta, aborted fetuses, vaginal discharges) through cuts or abrasions in the skin, or mucosal contact (conjunctiva). This is common for veterinarians, farmers, butchers, and abattoir workers.
    • Ingestion: Consumption of unpasteurized dairy products (milk, cheese, ice cream) from infected animals is the most common route in many endemic areas. Ingestion of undercooked meat is a less common route but possible.
    • Inhalation: Inhalation of aerosols in contaminated environments (e.g., slaughterhouses, laboratories) is a significant risk for occupational exposure.
    • Rare Routes: Human-to-human transmission is extremely rare but has been reported via breastfeeding, sexual contact, blood transfusion, bone marrow transplantation, or transplacental. Laboratory-acquired infections are also a concern.
  • Incidence: Varies widely by region. In endemic areas, incidence can be >10 cases per 100,000 population.

• Classification:

  • By Brucella species: B. melitensis, B. abortus, B. suis, B. canis.
  • By Clinical Course:
    • Acute: Onset within 8 weeks of infection, characterized by systemic symptoms (fever, malaise, myalgia).
    • Subacute: Symptoms persist for 2-12 months.
    • Chronic: Symptoms persist for >12 months, often with localized complications, or chronic fatigue syndrome-like symptoms. Relapse is considered part of the initial illness, not a new infection, if it occurs within the first year after treatment.

Pathophysiology

• Mechanism:

  1. Entry: Brucella enters the body via mucous membranes (gastrointestinal, respiratory, conjunctival) or broken skin.
  2. Lymphatic Spread: Bacteria are phagocytosed by macrophages and neutrophils and transported to regional lymph nodes, then disseminated hematogenously to the reticuloendothelial system (spleen, liver, bone marrow, lymph nodes).
  3. Intracellular Survival: A key virulence factor is the ability of Brucella to survive and multiply within phagocytic cells (macrophages, monocytes), evading destruction and immune responses. This intracellular localization protects the bacteria from many antibiotics and contributes to chronic infection and relapse.
  4. Granuloma Formation: Infection often leads to the formation of non-caseating granulomas in affected tissues (e.g., liver, spleen, bone marrow), similar to those seen in tuberculosis.
  5. Focal Manifestations: From the reticuloendothelial system, Brucella can spread to virtually any organ system, causing focal infections (e.g., bone and joint, genitourinary, neurological, cardiovascular).
  6. Immune Response: Both humoral and cell-mediated immunity are involved. Cell-mediated immunity is critical for controlling intracellular pathogens like Brucella.

• Risk Factors:

  • Occupational Exposure:
    • Farmers, ranchers, dairy workers, abattoir workers, butchers, veterinarians, laboratory personnel handling Brucella cultures.
    • Exposure to aborted animal fetuses, placentas, or uterine secretions.
  • Dietary Habits:
    • Consumption of unpasteurized milk, cheese, or other dairy products.
    • Ingestion of undercooked meat from infected animals.
  • Travel: Visiting endemic regions where unpasteurized dairy products are common.
  • Hunting: Exposure to wild game (e.g., wild boars, bison, elk) in some regions.
  • Laboratory Exposure: Inadvertent inoculation or aerosol exposure.

• Protective Factors:

  • Pasteurization: Heating milk and dairy products to specific temperatures kills Brucella species.
  • Animal Vaccination: Vaccination of livestock significantly reduces the prevalence of brucellosis in animal populations.
  • Safe Occupational Practices:
    • Use of personal protective equipment (gloves, masks, eye protection, protective clothing) when handling animals or animal products, especially during veterinary procedures or at slaughterhouses.
    • Proper waste disposal of animal tissues.
  • Food Safety Education: Public awareness campaigns about the risks of unpasteurized dairy products.
  • Biosafety Measures: Strict biosafety level (BSL-3) precautions for laboratory work involving Brucella cultures.

Clinical Presentation

The incubation period for brucellosis is highly variable, ranging from 1 week to several months, typically 2-4 weeks.

Signs and Symptoms

• Cardinal Features: Often non-specific, leading to diagnostic delays.

  • Fever: Classic "undulant" fever (rising in the evening, falling in the morning) is characteristic but not always present. Can be continuous, intermittent, or irregular.
  • Sweating: Profuse night sweats are very common, often described as having a "mousy" odor.
  • Malaise and Fatigue: Profound and persistent.
  • Arthralgia/Myalgia: Joint pain (often large joints), muscle aches. Sacroiliitis is a common finding.
  • Headache: Common and can be severe.
  • Anorexia and Weight Loss: Due to chronic illness.
  • Chills and Rigors.

• Early Signs: Typically flu-like symptoms: low-grade fever, malaise, myalgia, headache, anorexia.

• Advanced Signs (Focal Complications): Can occur in 20-60% of patients.

  • Musculoskeletal (10-85%):
    • Arthritis (sacroiliitis, peripheral arthritis, spondylitis). Spondylitis (affecting lumbar vertebrae most commonly) can lead to severe back pain, neurological deficits.
    • Osteomyelitis.
  • Genitourinary (2-20%):
    • Orchitis/Epididymo-orchitis (especially in males, unilateral or bilateral).
    • Prostatitis, pyelonephritis, nephritis.
  • Neurobrucellosis (3-25%):
    • Meningitis/meningoencephalitis (acute or chronic).
    • Radiculopathy, myelitis.
    • Peripheral neuropathy.
    • Cranial nerve palsies (e.g., facial nerve palsy).
    • Psychiatric manifestations (depression, anxiety).
    • Demyelinating syndromes.
  • Cardiovascular (1-2%):
    • Endocarditis (most serious complication, often affects aortic valve, leading cause of death in brucellosis).
    • Myocarditis, pericarditis.
  • Hepatic/Splenic (common, but often asymptomatic):
    • Hepatomegaly, splenomegaly (seen in 20-50%).
    • Liver abscesses (rare).
  • Hematologic (10-50%):
    • Anemia, leukopenia, thrombocytopenia (often mild).
    • Pancytopenia (rare).
  • Gastrointestinal (rare severe, common mild):
    • Nausea, vomiting, diarrhea, constipation, abdominal pain.
  • Respiratory (rare):
    • Bronchitis, pneumonia, pleural effusion, lung nodules/abscesses.
  • Ocular (rare): Uveitis, optic neuritis, endophthalmitis.
  • Dermatologic (rare): Rashes (maculopapular, erythematous, nodules).

• Atypical Presentations:

  • Chronic fatigue syndrome-like illness without clear focal signs.
  • Localized infection without systemic symptoms (e.g., isolated sacroiliitis).
  • Asymptomatic infection (serological evidence without clinical symptoms, more common in occupational exposure).

Physical Examination

• Inspection:

  • Fever and constitutional signs (fatigue, malaise).
  • Pallor (anemia).
  • Jaundice (rare, with hepatic involvement).
  • Rash (rare, non-specific maculopapular or erythematous lesions).
  • Swelling or erythema over joints (e.g., sacroiliac region, knees).
  • Testicular swelling (orchiepididymitis).
  • Signs of neurological deficit (e.g., gait disturbance, muscle weakness, facial asymmetry).

• Palpation:

  • Lymphadenopathy: Generalized or localized, common in cervical, axillary, inguinal regions.
  • Hepatosplenomegaly: Palpable liver and spleen, especially spleen. Tenderness over liver/spleen is less common.
  • Joint Tenderness: Tenderness and warmth over affected joints, particularly sacroiliac joints.
  • Spinal Tenderness: Localized tenderness over vertebrae in spondylitis.
  • Testicular Tenderness/Swelling: In cases of orchiepididymitis.

• Special Tests:

  • Neurological Examination: For suspected neurobrucellosis, assess mental status, cranial nerves, motor/sensory function, reflexes, coordination.
  • Cardiac Auscultation: Listen for new murmurs in suspected endocarditis.
  • Musculoskeletal Assessment: Range of motion, tenderness, and signs of inflammation in affected joints.

Diagnostic Approach

Brucellosis diagnosis requires a high index of suspicion due to its non-specific symptoms and varied clinical presentations, especially in non-endemic areas. A comprehensive approach combining history, laboratory tests, and imaging is crucial.

History Taking

• Key Questions:

  • Exposure History:
    • Occupation: Veterinarian, farmer, butcher, laboratory worker?
    • Animal contact: Direct contact with livestock (sheep, goats, cattle, pigs, dogs), especially during parturition, abortion, or handling carcasses?
    • Travel history: Recent travel to endemic regions?
  • Food Consumption:
    • Consumption of unpasteurized milk, cheese, or other dairy products?
    • Consumption of undercooked meat?
  • Symptom Onset and Pattern:
    • Fever pattern (undulant, continuous, intermittent)?
    • Presence and nature of sweating (especially night sweats)?
    • Musculoskeletal symptoms: Joint pain (location, character), back pain (location, severity, radiation)?
    • General symptoms: Fatigue, malaise, headache, anorexia, weight loss?
  • Focal Symptoms: Any neurological symptoms (headache, confusion, vision changes, weakness, numbness), cardiac symptoms (chest pain, shortness of breath), genitourinary symptoms (testicular pain/swelling), or other localized complaints?
  • Past Medical History: Any history of prior brucellosis or chronic illnesses?

• Red Flags:

  • Evidence of severe focal complications:
    • Neurological deficits: Acute onset of weakness, sensory changes, gait disturbance, altered mental status, seizures, cranial nerve palsies.
    • Signs of endocarditis: New heart murmur, signs of heart failure (dyspnea, peripheral edema).
    • Vertebral collapse or epidural abscess: Severe localized back pain with neurological deficits (e.g., motor weakness, sensory loss, bowel/bladder dysfunction).
    • Signs of acute abdomen: Suggesting hepatic or splenic abscess rupture.

Laboratory Tests

• First-Line (Screening and Initial Diagnosis):

  • Serology: The most commonly used diagnostic method.
    • Rose Bengal Test (RBT): Rapid slide agglutination test, good sensitivity for screening. Positive results require confirmation.
    • Standard Tube Agglutination Test (SAT): Gold standard serological test. Detects agglutinating antibodies (IgM and IgG). A single titer of ≥1:160 in a symptomatic patient from an endemic area or with appropriate exposure is suggestive. A four-fold or greater rise in titer between acute and convalescent sera (taken 2-4 weeks apart) is highly indicative of acute infection.
    • Enzyme-Linked Immunosorbent Assay (ELISA): Detects IgM, IgG, and IgA antibodies. More sensitive and specific than SAT, especially for detecting antibodies in chronic cases or for species other than B. abortus. IgM can remain elevated for long periods after acute infection. IgG is more indicative of active or recent infection.
  • Complete Blood Count (CBC):
    • Often shows normal WBC count, leukopenia, or lymphocytosis.
    • Mild anemia and/or thrombocytopenia may be present.
  • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Often elevated but non-specific. Useful for monitoring disease activity and response to treatment.
  • Liver Function Tests (LFTs): Mildly elevated transaminases, alkaline phosphatase may be seen due to hepatic involvement.

• Confirmatory (Gold Standard):

  • Culture: Definitive diagnosis. Brucella is slow-growing and requires specific culture media and prolonged incubation (up to 4 weeks, though most positive cultures are detected within 7-10 days).

    • Blood Culture: Yields positive results in 40-70% of acute cases (higher in B. melitensis infections). Needs specialized biphasic media or automated blood culture systems. Important: Inform the laboratory of suspected brucellosis due to biohazard risk (BSL-3 required).
    • Bone Marrow Culture: More sensitive than blood culture, especially in subacute/chronic cases or when blood cultures are negative (positive in 80-90%).
    • Culture from other sterile body fluids/tissues: CSF (neurobrucellosis), synovial fluid (arthritis), urine, abscess aspirates, tissue biopsies (e.g., lymph node, liver, spleen, vertebral disc).

  • Molecular Tests (PCR):

    • Polymerase Chain Reaction (PCR): Can detect Brucella DNA in blood, CSF, tissue biopsies, and other samples. Highly sensitive and specific, can provide rapid results, and may be positive when cultures are negative (e.g., in treated patients or those on antibiotics). Not yet a universally standardized diagnostic method but increasingly used.

• Monitoring:

  • Repeat Serology (SAT/ELISA IgG): To monitor treatment response (titers should decrease post-treatment) and detect relapse (rising titers). Note that serology may remain positive for extended periods even after successful treatment.
  • ESR/CRP: To monitor inflammatory response and treatment efficacy.
  • CBC and LFTs: To monitor for drug toxicity and overall hematologic/hepatic status.

Imaging

• Recommended (for suspected focal complications):

  • Plain Radiography (X-ray):
    • Spine: For spondylitis, may show osteolytic lesions, sclerosis, narrowed disc spaces, vertebral collapse, paravertebral abscesses. Sacroiliitis appears as erosions and sclerosis.
    • Peripheral Joints: For arthritis, may show effusions or periarticular changes.
  • Ultrasonography (US):
    • Abdomen: To evaluate hepatosplenomegaly, and rule out abscesses in the liver or spleen.
    • Scrotum: To diagnose orchiepididymitis (swelling, increased vascularity).
    • Heart: Transesophageal echocardiography (TEE) is preferred for suspected endocarditis due to higher sensitivity. Transthoracic echocardiography (TTE) can be used as an initial screening tool.

• Advanced (for specific, complex focal complications):

  • Magnetic Resonance Imaging (MRI):
    • Spine/Brain: Gold standard for neurobrucellosis and spinal complications. Provides detailed visualization of spinal lesions, discitis, epidural abscesses, vertebral collapse, meningitis, encephalitis, and demyelinating lesions.
    • Joints: Better for soft tissue and early inflammatory changes in peripheral joints and sacroiliac joints.
  • Computed Tomography (CT):
    • Abdomen: For better visualization of hepatic/splenic abscesses or lymphadenopathy if US is equivocal.
    • Brain: For space-occupying lesions or hydrocephalus in neurobrucellosis, though MRI is superior for most neurobrucellosis findings.
  • Positron Emission Tomography (PET-CT): Used in select complex cases, particularly to identify active inflammatory foci, evaluate multifocal osteoarticular involvement, or detect occult abscesses, and monitor treatment response in chronic cases.

Management

The cornerstone of brucellosis management is prolonged combination antibiotic therapy due to the intracellular nature of the bacteria and the high risk of relapse with monotherapy.

Acute Management

• Immediate:

  • Upon strong clinical suspicion and positive serology (while awaiting culture confirmation), initiate appropriate antibiotic therapy promptly to prevent complications and reduce symptom duration.
  • No specific "first-hour" interventions unless severe complications (e.g., septic shock, acute neurological deterioration) requiring immediate supportive care, which are rare at presentation for brucellosis itself.

• Stabilization:

  • Symptomatic relief: Antipyretics for fever, analgesics for pain.
  • Hydration and nutritional support if patient is debilitated.
  • Assessment for focal complications that might require urgent intervention (e.g., neurological assessment, cardiac assessment).

• Emergency:

  • Management of severe complications:
    • Brucella Endocarditis: Often requires surgical valve replacement in addition to prolonged antimicrobial therapy (e.g., 3-4 drug regimen for 3-6 months or longer).
    • Large Abscesses (hepatic, splenic, paravertebral): May require percutaneous drainage or surgical debridement in addition to antibiotics.
    • Spinal Cord Compression: Due to spondylitis or epidural abscess, may necessitate urgent surgical decompression.
    • Hydrocephalus in Neurobrucellosis: Ventriculoperitoneal shunt may be required.

Chronic Management

• Pharmacological (Antibiotic Regimens):

  • General Principles:
    • Combination Therapy: Essential to prevent relapse due to intracellular survival.
    • Prolonged Duration: To eradicate intracellular bacteria.
    • Drug Selection: Based on efficacy, toxicity, patient age, and special populations (e.g., pregnancy).

  • Recommended Regimens (WHO/IDSA Guidelines):

    1. Doxycycline + Rifampin (Oral Regimen):
       • Doxycycline: 100 mg orally twice daily.
       • Rifampin: 600-900 mg orally once daily (or 15 mg/kg up to 900 mg).
       • Duration: 6 weeks for uncomplicated brucellosis.
       • Advantages: All oral, well-tolerated generally.
       • Disadvantages: Rifampin interacts with many drugs (CYP inducer), Doxycycline can cause photosensitivity, GI upset.
    2. Doxycycline + Streptomycin/Gentamicin (Parenteral + Oral Regimen):
       • Doxycycline: 100 mg orally twice daily.
       • Streptomycin: 1 gram intramuscularly once daily for 14-21 days (or 15 mg/kg up to 1 gram).
       • OR Gentamicin: 5 mg/kg intravenously/intramuscularly once daily for 7-10 days.
       • Duration: Doxycycline for 6 weeks; Aminoglycoside for 1-3 weeks.
       • Advantages: Higher efficacy, especially for B. melitensis, and potentially lower relapse rates. Preferred for complicated cases.
       • Disadvantages: Parenteral administration (Streptomycin/Gentamicin), risk of ototoxicity and nephrotoxicity with aminoglycosides.

  • Specific Complications & Regimen Adjustments:

    • Spondylitis: Doxycycline + Rifampin for 3-4 months, potentially adding a third agent (e.g., ciprofloxacin) for the initial 2-4 weeks, or Doxycycline + Streptomycin/Gentamicin for 4-6 weeks followed by Doxycycline + Rifampin for total of 3-4 months.
    • Neurobrucellosis: Triple therapy recommended: Doxycycline + Rifampin + Ceftriaxone (or Cotrimoxazole).
      • Doxycycline: 100 mg orally twice daily.
      • Rifampin: 600-900 mg orally once daily.
      • Ceftriaxone: 1-2 grams intravenously once daily.
      • Duration: At least 4-6 months, potentially longer, depending on clinical response and CSF parameters.
      • Corticosteroids may be considered for severe inflammatory reactions (e.g., meningitis, radiculopathy, myelitis).
    • Endocarditis: Combination of 3 antibiotics (e.g., Doxycycline + Rifampin + an aminoglycoside, possibly with a quinolone or cotrimoxazole) for at least 3-6 months, often lifelong suppression may be considered. Surgical valve replacement is frequently necessary.
    • Children (>8 years): Doxycycline + Rifampin as adult doses.
    • Children (<8 years) & Pregnant Women: See "Special Populations" below.

• Non-pharmacological:

  • Rest: During the acute phase, rest is important for recovery.
  • Pain Management: Analgesics and anti-inflammatory drugs for arthralgia/myalgia.
  • Physical Therapy: For musculoskeletal complications (e.g., spondylitis, arthritis) to restore function and prevent chronic disability.
  • Psychological Support: For chronic fatigue, depression, or anxiety that can accompany chronic brucellosis.

• Monitoring:

  • Clinical Response: Monitor for resolution of fever, constitutional symptoms, and improvement of focal symptoms.
  • Laboratory:
    • CBC, LFTs, Renal Function: Regularly monitor for drug toxicity (e.g., hepatic dysfunction with Rifampin, renal/ototoxicity with aminoglycosides).
    • ESR/CRP: Should decrease with successful treatment.
    • Serology (SAT/ELISA IgG): Titer should decline slowly but may remain elevated for months or years. A rising titer after treatment suggests relapse. Cultures should become negative.
  • Imaging: Repeat imaging (e.g., MRI for spondylitis) to assess resolution of focal lesions.

Treatment Algorithms

• First-Line (Uncomplicated Brucellosis):

  1. Doxycycline 100 mg PO BID + Rifampin 600-900 mg PO QD for 6 weeks.
  2. Doxycycline 100 mg PO BID for 6 weeks + Streptomycin 1 g IM QD for 14-21 days (or Gentamicin 5 mg/kg IV/IM QD for 7-10 days).
     • Consider for severe cases or B. melitensis infections where higher efficacy is desired, or when adherence to Rifampin is a concern.

• Second-Line (or Alternatives for specific situations):

  1. Ciprofloxacin 500-750 mg PO BID + Rifampin 600-900 mg PO QD for 6 weeks. (Less favored due to higher relapse rates than Doxycycline regimens, but an option if Doxycycline is contraindicated or not tolerated).
  2. Cotrimoxazole (Trimethoprim-sulfamethoxazole) (TMP-SMX) 8/40 mg/kg/day PO BID (max 160/800 mg BID) + Rifampin 600-900 mg PO QD for 6 weeks. (Alternative for Doxycycline intolerance, or for children <8 years and pregnant women as per special populations section).

• Refractory Cases (Treatment Failure or Relapse):

  • Re-evaluate Diagnosis: Confirm Brucella infection (re-culture, PCR). Rule out other causes of symptoms.
  • Assess Adherence: Major cause of treatment failure.
  • Prolonged Therapy: Extend duration of combination therapy (e.g., to 3-6 months).
  • Switch Regimen: Change to a different highly effective combination (e.g., switch from Doxycycline/Rifampin to Doxycycline/Aminoglycoside).
  • Triple Therapy: For persistent or recurrent complicated cases, consider adding a third drug (e.g., a quinolone like Ciprofloxacin) to Doxycycline and Rifampin, or a regimen with an aminoglycoside + two other agents.
  • Surgical Intervention: For persistent focal lesions (e.g., undrained abscesses, endocarditis, spondylitis with neurological compromise).

Complications

Complications can be severe and affect virtually any organ system.

• Common:

  • Relapse: Occurs in 5-20% of cases, primarily due to inadequate duration or inappropriate choice of antibiotics, or poor patient adherence. Typically within 6 months of stopping treatment.
  • Osteoarticular Involvement: Arthritis (sacroiliitis, peripheral arthritis), spondylitis, osteomyelitis. Most common focal complication.
  • Epididymo-orchitis: In males.
  • Hepatomegaly/Splenomegaly: Often asymptomatic but common.
  • Fatigue and Malaise: Can persist for months after successful treatment.

• Serious:

  • Endocarditis: Most serious and life-threatening complication, especially involving the aortic valve. Accounts for the majority of brucellosis-related deaths. Requires aggressive medical and often surgical management.
  • Neurobrucellosis: Meningitis (acute or chronic), meningoencephalitis, radiculopathy, myelitis, brain abscesses, psychiatric disorders. Can lead to permanent neurological deficits.
  • Spondylitis with Neurological Compromise: Vertebral collapse, epidural abscess leading to spinal cord compression.
  • Abscess Formation: Hepatic, splenic, paravertebral, psoas, or brain abscesses.
  • Pancreatitis: Rare but reported.
  • Ocular Involvement: Uveitis, optic neuritis, vision loss.
  • Pancytopenia: Severe bone marrow suppression.

• Long-term:

  • Chronic pain from osteoarticular involvement.
  • Chronic fatigue syndrome.
  • Depression and anxiety.
  • Permanent neurological deficits (e.g., gait abnormalities, motor weakness).
  • Infertility (rare, secondary to severe orchitis).
  • Chronic liver disease (rare).

Prognosis

• Factors:

  • Species of Brucella: B. melitensis is associated with more severe disease and a higher rate of complications compared to B. abortus.
  • Promptness and Adequacy of Treatment: Early diagnosis and appropriate, prolonged combination antibiotic therapy significantly improve outcomes and reduce relapse rates.
  • Presence of Focal Complications: The development of focal complications, especially endocarditis and neurobrucellosis, significantly worsens the prognosis and increases mortality.
  • Host Factors: Immunocompromised patients may have a more severe course.

• Survival:

  • With appropriate treatment, the mortality rate for uncomplicated brucellosis is very low (<1%).
  • Mortality significantly increases with complications, especially brucella endocarditis (which can be 20-80% without surgery) and severe neurobrucellosis.
  • Overall mortality for treated brucellosis is generally <2%.

• Quality of Life:

  • While mortality is low, the morbidity can be substantial. Patients can experience prolonged illness, chronic fatigue, recurrent pain, and psychological distress.
  • Focal complications can lead to permanent organ damage or disability, significantly impacting quality of life.

Prevention

Prevention strategies focus on controlling the disease in animal reservoirs and preventing transmission to humans.

• Primary Prevention: Preventing initial infection.

  • Animal Vaccination: Large-scale vaccination programs for livestock (e.g., B. abortus S19, RB51; B. melitensis Rev-1) are crucial for controlling the disease at its source.
  • Test and Slaughter Programs: In some countries, infected animals are identified and culled to eradicate the disease from herds.
  • Pasteurization: Heating milk and dairy products (at least 72°C for 15 seconds, or 63°C for 30 minutes for batch pasteurization) effectively kills Brucella bacteria. Public education campaigns promoting the consumption of pasteurized products.
  • Food Safety Practices: Avoid consuming unpasteurized dairy products. Cook meat thoroughly.
  • Occupational Safety:
    • Use of personal protective equipment (gloves, masks, protective clothing, eye protection) when handling animals, animal carcasses, products of conception (placenta, aborted fetuses), or laboratory cultures.
    • Proper disposal of contaminated materials.
    • Strict adherence to biosafety level (BSL-3) protocols in laboratories handling Brucella.
  • Traveler Education: Advise travelers to endemic areas to avoid unpasteurized dairy products.
  • No Human Vaccine Available: Currently, there is no effective and safe vaccine for human brucellosis.

• Secondary Prevention: Early detection and intervention.

  • Surveillance: Active surveillance in animal populations and human populations at high risk (e.g., occupational groups) for early detection.
  • Prompt Diagnosis and Treatment: Early diagnosis of symptomatic individuals and initiation of appropriate combination antibiotic therapy to prevent chronic forms and complications.

• Tertiary Prevention: Preventing complications and improving outcomes in infected individuals.

  • Adherence to Treatment: Ensuring patients complete the full course of combination antibiotic therapy to minimize relapse.
  • Monitoring for Relapse and Complications: Regular follow-up to detect signs of relapse or new complications early.
  • Rehabilitation: Physical therapy for musculoskeletal complications, psychological support for chronic fatigue/depression.

Special Populations

• Pediatric:

  • Diagnosis: Can be challenging due to non-specific symptoms. Serology (SAT, ELISA) is standard. Culture from blood/bone marrow is important.
  • Treatment:
    • Children >8 years: Doxycycline 2-4 mg/kg/day PO (max 100 mg/day) + Rifampin 15-20 mg/kg/day PO (max 600-900 mg/day) for 6 weeks. Doxycycline is generally safe in children >8 years, and the risk of dental staining is outweighed by the severity of the disease.
    • Children <8 years: Tetracyclines (Doxycycline) are generally avoided due to potential for permanent dental staining.
      • Recommended: Cotrimoxazole (TMP-SMX) 8/40 mg/kg/day (TMP component) PO BID + Rifampin 15-20 mg/kg/day PO (max 600-900 mg/day) for 6 weeks.
      • For severe cases or B. melitensis: Consider adding Gentamicin 5 mg/kg IV/IM once daily for 7-10 days to the Cotrimoxazole + Rifampin regimen.
  • Complications: Similar to adults, but osteoarticular involvement (especially peripheral arthritis) is common.

• Geriatric:

  • Diagnosis: May be difficult due to atypical presentation and comorbidities masking symptoms.
  • Treatment: Standard regimens generally apply.
    • Careful consideration of polypharmacy and drug-drug interactions (e.g., Rifampin).
    • Monitor for increased risk of aminoglycoside nephrotoxicity and ototoxicity due to age-related decline in renal function.
    • Adjust drug dosages based on renal and hepatic function.
  • Complications: Higher risk of severe complications and poorer outcomes, especially if underlying comorbidities exist.

• Pregnancy:

  • Diagnosis: Similar to non-pregnant adults. Serology is safe.
  • Treatment: Avoid Doxycycline (teratogenic effects: dental discoloration, bone development inhibition) and aminoglycosides (ototoxicity to fetus).
    • Recommended: Rifampin 600-900 mg PO QD + Cotrimoxazole (TMP-SMX) 160/800 mg PO BID.
      • Duration: Typically 6 weeks.
      • Important: Cotrimoxazole should be avoided in the first trimester (due to folate antagonism) and near term (risk of kernicterus in neonate).
      • If Cotrimoxazole cannot be used, Rifampin monotherapy for 6 weeks may be considered for mild cases (higher relapse risk).
      • Another option for severe cases (if benefits outweigh risks) may be combinations like Rifampin + Gentamicin, but with close monitoring of the fetus.
  • Complications: Brucellosis during pregnancy increases risk of abortion, premature labor, fetal distress, and congenital infection. Treat aggressively to prevent these.

• Comorbidities:

  • Immunocompromised Patients: May require longer treatment durations and close monitoring for relapse. Triple therapy may be considered for initial treatment.
  • Renal or Hepatic Impairment: Adjust dosages of renally (aminoglycosides, Doxycycline) or hepatically (Rifampin) cleared drugs. Careful monitoring of drug levels and organ function.

Clinical Pearls

• Diagnostic:

  • Think Brucellosis: In any patient with fever of unknown origin (FUO), especially with musculoskeletal symptoms (arthralgia, spondylitis), night sweats, and a relevant exposure history (travel to endemic area, consumption of unpasteurized dairy, occupational animal contact).
  • Serology First: SAT or ELISA are the initial diagnostic tests, but require careful interpretation. A single high titer (≥1:160) in a compatible clinical setting is suggestive.
  • Culture is Gold Standard: Always attempt to culture Brucella from blood, bone marrow, or other sterile sites. Inform the lab of suspicion due to biohazard risk.
  • Focal Complications Often Missed: Be vigilant for signs of neurobrucellosis, endocarditis, or spondylitis, as these dictate treatment duration and may require imaging.

• Treatment:

  • Combination Therapy is Key: Never use monotherapy for acute brucellosis due to high relapse rates.
  • Prolonged Duration: At least 6 weeks for uncomplicated cases, much longer (months) for focal complications like spondylitis, endocarditis, or neurobrucellosis.
  • Adherence: Emphasize the importance of completing the full course of antibiotics, even if symptoms resolve quickly. Relapse is common with non-adherence.
  • Drug Interactions: Be aware of Rifampin's potent enzyme-inducing properties, affecting metabolism of many drugs (e.g., oral contraceptives, anticoagulants).

• Pitfalls:

  • Misdiagnosis: Due to non-specific symptoms, often mistaken for other febrile illnesses, leading to delayed or incorrect treatment.
  • Inadequate Treatment: Short courses, monotherapy, or incorrect drug combinations significantly increase relapse rates.
  • Ignoring Focal Symptoms: Failure to identify and treat focal complications can lead to severe and irreversible damage.
  • Over-reliance on Serology for Cure: Persistently elevated antibody titers after treatment do not necessarily mean treatment failure or active infection; clinical improvement and negative cultures are more reliable indicators. A rising titer, however, suggests relapse.
  • Laboratory Safety: Not informing the lab of suspected Brucella can lead to laboratory-acquired infections.

Recent Updates

• Guidelines: Current treatment guidelines from the World Health Organization (WHO), Infectious Diseases Society of America (IDSA), and Centers for Disease Control and Prevention (CDC) generally remain consistent regarding combination therapy and prolonged duration. There's a continuous emphasis on the Doxycycline + Rifampin or Doxycycline + Aminoglycoside regimens as first-line.
• Evidence:
  • Increasing use of molecular diagnostic methods (PCR) for rapid diagnosis, especially for difficult-to-culture samples or in early stages of infection. While not yet universally standardized, it's becoming a valuable adjunct.
  • Studies continue to explore optimal treatment durations for specific focal complications, and the role of adjunctive therapies (e.g., corticosteroids for neurobrucellosis) is being refined.
  • Research on new antimicrobial agents and vaccine development for humans is ongoing but no major breakthroughs for clinical use yet.
• Controversies:
  • Optimal duration of treatment for some focal forms (e.g., chronic spondylitis, endocarditis).
  • The role and benefit of triple therapy in non-complicated cases versus standard dual therapy.
  • The interpretation of serological titers post-treatment and their utility in predicting relapse versus persistent seropositivity.

Key References

• Guidelines:

  • World Health Organization (WHO): Brucellosis in humans and animals. WHO document WHO/CDS/CSR/APH/2006.3. (While older, it remains a foundational reference for global guidelines).
  • Infectious Diseases Society of America (IDSA): Guidelines for the Diagnosis and Management of Brucellosis (often incorporated into general infectious disease guidelines; no standalone specific IDSA guideline currently).
  • Centers for Disease Control and Prevention (CDC): Information on Brucellosis for clinicians.

• Studies:

  • Araj, G. F. (2010). Update on laboratory diagnosis of human brucellosis. International Journal of Antimicrobial Agents, 36(Supplement 1), S12-S17. (Focus on diagnostic advancements).
  • Pappas, G., et al. (2005). Brucellosis. The New England Journal of Medicine, 352(22), 2325-2336. (Classic comprehensive review).
  • Hasanjani, R. M., et al. (2018). An update on the treatment of human brucellosis. Journal of Research in Medical Sciences, 23. (Review of treatment strategies).

• Reviews:

  • Corbel, M. J. (2006). Brucellosis: an overview. Emerging Infectious Diseases, 12(7), 1121-1128.
  • Young, E. J. (1995). An overview of human brucellosis. Clinical Infectious Diseases, 21(2), 283-290. (Classic review on clinical aspects).
  • Colmenero, J. D., et al. (1996). Complications associated with brucellosis: a study of 530 cases. Medicine, 75(4), 195-211. (Detailed study on complications).